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Serum Dehydroepiandrosterone Sulfate Usage for Early
Detection of Prostate Cancer in Men with Serum
Prostate Specific Antigen Level between 2.5 and
4.0 ng/ml: A Pilot Study
Aims: We prospectively evaluated the diagnostic value of serum prostate specific antigen (PSA)-based
diagnostic parameters and serum dehydroepiandrosterone sulfate (DHEAS) level for early detection of
prostate cancer in patients with serum PSA level between 2.5 and 4 ng/ml.
Materials and Methods: This study included 83 consecutive men with serum PSA levels between 2.5 and
4.0 ng/ml. All patients underwent transrectal ultrasound-guided prostate needle biopsy. Total PSA level,
free/total PSA ratio, PSA density of the total volume (PSAD-TV), PSA density of the transition zone (PSADTZ), and serum DHEAS values were determined.
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Results: Seventy-four patients (89.2%) had histopathologically confirmed benign prostatic hyperplasia and
the remaining (10.8%) had prostate cancer. DHEAS was a significant predictor of prostate cancer compared
to free/total PSA ratio, PSAD-TV and PSAD-TZ (PDHEAS = 0.012, Pfree/total PSA = 0.326, PPSAD-TV = 0.884, PPSAD-TZ
= 0.203). If the cut-off point of DHEAS was considered 1,700 ng/ml, sensitivity and specificity of DHEAS were
100% and 59.4%, respectively. This cut-off point might lead to avoiding 40.9% of unnecessary prostate
biopsies.
Conclusions: Serum DHEAS seems to be a reasonable marker for early detection of prostate cancer and can
avoid unnecessary prostate biopsy in patients whose serum PSA level is between 2.5 and 4 ng/ml.
Key Words: Prostate cancer, prostate specific antigen, dehydroepiandrosterone sulfate

Serum Prostat Spesifik Antijen Düzeyi 2.5-4 ng/mL Arasında Olan Erkeklerde
Prostat Kanserinin Erken Tanısı İçin Serum Dihidroepiandrosteron
Sülfat Kullanımı: Pilot Çalışma
Amaç: Prostat spesifik antijen (PSA) düzeyi 2.5-4 ng/mL arasında olan hastalarda prostat kanserinin erken
tanısı için PSA bağımlı tanısal değişkenler ve dihidroepiandrosteron sülfat’ın (DHEAS) tanısal değerini
inceledik.
Yöntem ve Gereç: Bu çalışmaya PSA düzeyi 2.5-4 ng/mL arasında olan 83 erkek dahil edildi. Tüm hastalara
transrektal ultrasonografi eşliğinde prostat iğne biyopsisi yapıldı. Total PSA düzeyi, free/total PSA oranı, total
volum PSA dansitesi (PSAD-TV), transizyonel zon PSA dansitesi (PSAD-TZ) ve serum DHEAS düzeyleri
belirlendi.
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Bulgular: Yetmişdört hastada (% 89.2) histopatolojik olarak benign prostat hiperplazisi ve geri kalanlarda
(%10.8) prostat kanseri saptandı. DHEAS prostat kanseri için free/total PSA oranı, PSAD-TV ve PSAD-TZ ile
karşılaştırıldığında anlamlı bir belirleyiciydi (PDHEAS = 0.012, Pfree/total PSA = 0.326, PPSAD-TV = 0.884, PPSAD-TZ =
0.203). DHEAS için kestirim noktası 1,700 ng/ml düşünülseydi, duyarlılık ve seçicilik sırasıyla % 100 ve %
59.4 olurdu. Bu kesitirim değeri % 40.9 gereksiz prostat biyopsisinden kaçınmayı sağlayabilirdi.
Sonuç: Serum DHEAS, serum PSA düzeyi 2.5-4 ng/mL arasında olan hastalarda prostat kanserinin erken
tanısı ve gereksiz prostat biyopsisinden kaçınabilmek için makul bir belirleyici gibi görünmektedir.
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Introduction
Prostate cancer is the most common estimated cancer among men and is alone
responsible for approximately 33% of incidental cases in men (1). Regular serum
prostate specific antigen (PSA) evaluation and digital rectal examination (DRE) are
recommended for detecting prostate cancer (2). When a serum total PSA cut-off level
399
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for biopsy of either 2.5 or 4.0 ng/ml is used, positive
predictive values are similar (3,4). Thus, to avoid
unnecessary biopsies in these patients and to detect
prostate cancer more precisely, novel tumor markers are
needed.
The major androgen in the male circulation is
testosterone, 95% of which is from the testicles;
adrenalin glands produce the remaining 5%.
Dehydroepiandrosterone
(DHEA)
and
dehydroepiandrosterone sulfate (DHEAS), androgens of
adrenalin origin, reach their plasma peak levels at about
25 years of age and decrease by 95% of the peak level at
the age of 85 (5). Various prospective and retrospective
studies have shown that decreased serum levels of DHEA
and its sulfated compounds increase the risk of cancers
such as breast, ovarian, and bladder cancers (6-9).
The aim of the present study was to investigate the
efficacy of using serum DHEAS level in patients with
serum total PSA level ranging from 2.5 to 4.0 ng/ml in
the diagnosis of prostate cancer.

Materials and Methods
Between May 2001 and June 2007, 83 consecutive
patients with serum total PSA levels between 2.5 and 4.0
ng/ml and/or abnormal DRE findings were included in this
study. The patients underwent prostate biopsy under the
guide of transrectal prostate ultrasonography (TRUS).
Exclusion criteria were: previous prostate biopsy,
previous treatment for chronic prostatitis, bladder
tumor, active urinary tract infection, history of
finasteride usage within the last year, ejaculation in the
last 24 hours, urethral catheter associated with urinary
retention, use of anticoagulant drugs, chronic liver and/or
kidney disease, and any endourological procedure in the
last 45 days.
Before the biopsy procedure, blood samples were
taken by venipuncture from the antecubital region.
Serum total and free PSA levels were measured by
chemiluminescence method (Roche Diagnostics® GmbH,
Germany; reference value: 0-4.0 ng/ml). Serum DHEAS
was evaluated with Elecysis 2010. Serum DHEAS levels
between 240 and 4920 ng/ml for those aged 10 to 19
years, 900 and 4920 ng/ml for those 20 to 44 years, and
400 and 3310 ng/ml for those 45 to 75 years are
considered normal using this method.
400
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Following blood collection, the patients underwent
DRE. The presence of asymmetry, nodule in the prostate
and/or irregularity of prostate contour were considered
as abnormal findings. TRUS and biopsy procedures were
performed using a 7.5 mHz biplane transrectal probe on
Hitachi EUB 420 (Hitachi, Japan) ultrasonography device.
The patients were in left decubitus position during the
procedure. Hypoechoic area on TRUS and/or contour
irregularities in the prostate were considered abnormal
findings. To calculate total prostatic volume (TV) and
transitional zone (TZ) volume of the prostate, ellipsoid
formula was used at the time of TRUS.
During the biopsy procedure, an 18-gauge automatic
prostate biopsy needle was used. In addition to sextant
biopsy, lateral and far lateral biopsies were taken, two
from each gland.
The patients were divided into two groups according
to their histopathological results as those with prostate
cancer (Group 1, n=9) and those without prostate cancer
(Group 2, n=74). The groups were compared regarding
age, serum total and free PSA levels, free/total PSA ratio,
serum DHEAS levels, TV, TZ, and PSA density of the
whole prostate (PSAD-TV) and of the transition zone
(PSAD-TZ).
Statistical Analysis
Statistical Package for Social Sciences for Windows
(SPSS, Chicago, USA) version 13.0 software was used for
statistical evaluation of the results. The comparisons were
performed by using Mann-Whitney test. Receiver
Operating Characteristics (ROC) curve was drawn to
evaluate the performance of serum DHEAS in diagnosing
prostate cancer and to determine the best cut-off value
for serum DHEAS. The sensitivity, specificity and positive
predictive values were calculated. A P value less than 0.05
was considered statistically significant.

Results
The mean age of the patients was 62.6±7.01 (range:
45 to 74) years. The mean age in Groups 1 and 2 were
65.3±7.8 (range: 50 to 74) and 62.3±6.9 (range: 45 to
73) years, respectively (P: 0.170). There was no
significant difference in terms of serum total PSA level,
free/total PSA ratio, TV, TZ, PSAD-TV, and PSAD-TZ
values between the groups. The demographic
characteristics of the patients are shown in Table.
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Table. Patients’ demographic data.

PARAMETERS

Group 1
(Mean ± SD)

Group 2
(Mean ± SD)

P value

Age (year)

65.33 ± 7.84
(50-74)

62.27 ± 6.89
(45-73)

0.17

PSA (ng/ml)

3.34 ± 0.54
(2.54-4.0)

3.19 ± 0.44
(2.5-3.96)

0.368

Free/total PSA ratio

0.26 ± 0.17
(0.07-0.68)

0.19 ± 0.11
(0.04-0.77)

0.326

DHEAS (ng/ml)

953 ± 500
(148-1683)

1967 ± 1096
(96-3906)

0.012*

PSAD-TV

0.07 ± 0.02
(0.05-0.11)

0.08 ± 0.3
(0.02-0.17)

0.884

PSAD-TZ

0.20 ± 0.08
(0.11-0.32)

0.18 ± 0.11
(0.04-0.47)

0.203

TV

46.68 ± 6.56
(35-55)

50.24 ± 25.94
(21-205)

0.72

TZ

18.22 ± 5.64
(9-27)

24.13 ± 15.51
(7-100)

0.337

Data presented as mean ± standard deviation with minimum-maximum values in parentheses.
SD: standard deviation PSA: prostate specific antigen DHEAS: dehydroepiandrosterone sulfate PSA-TV: prostate specific antigen density of the whole
prostate PSA-TZ: prostate specific antigen density of the transitional zone TV: total volume of the prostate TZ: transitional zone volume of the
prostate.

At the end of the histopathological evaluation,
prostate cancer was detected in 9 (10.8%) of the
patients. In the evaluation of DRE findings, 25 (30.1%)
of 83 patients had abnormal and 58 (69.9%) had normal
findings. In Group 1, 4 (44.4%) patients had normal and
the remaining (55.6%) had abnormal DRE findings. In
Group 2, 54 (73%) patients had normal and 20 (27%)
had abnormal DRE findings. The sensitivity, specificity
and positive predictive value of DRE were 55.6%, 73%,
and 20%, respectively.
In Group 1, TRUS findings were normal in 3 (33.3%)
patients and abnormal in 6 (66.7%) patients. In Group 2,
66 (89.2%) and 8 (10.8%) patients had normal and
abnormal TRUS findings, respectively. Prostate cancer
was diagnosed in 6 (42.9%) of the 14 patients with
abnormal TRUS findings. The sensitivity, specificity, and
positive predictive value of TRUS were 67.7%, 89.2%,
and 42.9%, respectively.

The mean DHEAS level in patients with prostate
cancer was 953±500 (range: 148 to 1,683), and the
mean DHEAS level in patients without prostate cancer
was 1,967±1,096 (range: 96 to 3,906) ng/ml (P:
0.012). According to the ROC analysis, the best cut-off
value of serum DHEAS was found as 1,700 ng/ml. Area
under the ROC curves for serum DHEAS level was 0.758
(95% confidence interval [CI]: 0.649-0.868, P: 0.012)
(Figure). When the cut-off value of DHEAS was
considered as 1,700 ng/ml, the sensitivity and specificity
of DHEAS were 100% and 59.4%, respectively.

Discussion
Serum total PSA level, DRE, and TRUS are the bestknown diagnostic tools for prostate cancer. The role of
TRUS in prostate cancer diagnosis has been debated. The
most significant indication of TRUS is its guidance in
needle biopsy procedures on systematic or suspected
401
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Figure 1. The ROC curve for serum DHEAS level.
DHEAS: Dehydroepiandrosterone sulfate

areas. Nevertheless, both DRE and TRUS may lead to
false-negative or false-positive results. DRE has been
reported to have a positive predictive value of 21-53%
(10-11). Ellis et al. (12) reported the diagnostic reliability
of hypoechoic lesion on peripheral zone (PZ) as 43%,
sensitivity as 85.5%, specificity as 28.4%, and positive
predictive value as 29%. Our results in the present study
were in agreement with their study.
Serum total PSA is one of the most commonly used
tumor markers. It offers a contribution to the early
diagnosis of prostate cancer (10). However, the cut-off
value of serum total PSA level for prostate biopsy has
been a matter of extensive debate. When total PSA cutoff level is considered high, some clinically important
cancers may be overlooked. In contrast, when it is
considered low, unnecessary biopsies would increase with
associated morbidity and cost. The upper limit of serum
total PSA level is usually considered as 4.0 ng/ml.
However, approximately 20% of prostate cancer patients
have serum total PSA levels below 4 ng/ml (13). In some
studies, prostate cancer detection rate was between 228% in patients who had less than 4.0 ng/ml serum PSA
level (14-16). Thus, patient selection, core number, core
localization, and the suitable re-biopsy time are still
controversial issues in prostate biopsy (17). Colberg et al.
(18) reported that prostate cancer detection rate was
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7.2% in 121 volunteers with suspicious DRE and/or
TRUS and serum total PSA level between 2.9-4.0 ng/ml.
Catalona and co-workers (13) diagnosed prostate cancer
in 22% of 332 patients with serum total PSA level
between 2.6-4.0 ng/ml, but they did not detect suspicious
DRE and/or TRUS findings. In a study by Babaian et al.
(14), 151 volunteers had serum total PSA value between
2.5-4.0 ng/ml, and prostate cancer was found in 24.5%
of them. Another study evaluated 883 patients with
serum total PSA level between 2.0-3.9 ng/ml, and
prostate cancer rate was 14.3% (19). Clinically
important cancers, 20% of which were beyond prostate,
were reported in 89% of the patients with serum total
PSA level less than 4.0 ng/ml (14). In the patients with
serum total PSA value of 2.5-4.0 ng/ml, free/total PSA
ratio, TV, TZ, PSAD-TV, and PSAD-TZ evaluations have
not been described as fully efficient in differentiation of
prostate cancer from benign disorders of the prostate
(20,21). Thus, there is no parameter with verified
efficacy in the diagnosis of prostate cancer. Since these
parameters yielded similar results in both groups, new
parameters are needed.
There are some studies in the international literature
about serum DHEAS and the prostate cancer relationship.
In a study by Stahl and colleagues (22), serum DHEA level
was significantly lower in prostate cancer patients than in
those without prostate cancer. In a study by Comstock et
al. (23), low serum DHEAS levels were detected in 11%
and 12% of the patients in the prostate cancer group and
control group, respectively, with no significant difference
between the groups. They thus concluded that serum
DHEA and DHEAS levels were not a risk factor for
prostate cancer. In contrast, two current studies found
that serum DHEA levels were significantly lower in black
patients than whites (24,25). They claimed that black
patients are more prone to develop prostate cancer due
to low serum DHEA level. On the other hand, Eaton et al.
(26) evaluated the changes in the sex hormone values of
patients with prostate cancer and normal men in a series
of eight prospective epidemiological studies, and they
found no difference between the serum DHEAS levels in
the two groups. In another study, no significant
difference was found in terms of serum DHEAS levels
between patients with prostate cancer and benign disease
(27). In our study, serum DHEAS levels in the prostate
cancer group were significantly lower than those of the
benign group. In this pilot study, we also aimed to
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determine a clinical cut-off value for serum DHEAS level.
To this end, a ROC curve was prepared and the best cutoff value of DHEAS was found to be 1,700 ng/ml.
Prostate cancer diagnosis was not missed in our patients
using this cut-off value.
Another important result of our study is that 10.8%
of the patients had histopathologically proven prostate
cancer. Our prostate cancer rate was lower than in the
international literature. Two studies from our country
revealed that the age-adjusted PSA reference ranges are
greater than those universally accepted, and the prostate
cancer detection rate is surprisingly low (17.5% versus
7.5%) in the PSA ranges between 4.0 and 10.0 ng/ml
(28,29). In addition to ethnic characteristics, prostatic
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calculi and prostate inflammation may be contributing
factors to PSA elevation (28,30).
In the present study, prostate cancer was detected in
10.8% of the patients. Serum DHEAS level may be useful
in the differentiation of malignant and benign diseases of
the prostate. Our results showed that low DHEAS level
might be considered as a parameter before planning for a
biopsy procedure in patients with serum total PSA level
between 2.5 and 4.0 ng/ml. To our knowledge, our study
is the first regarding early diagnosis of prostate cancer
based on serum DHEAS levels in patients with serum total
PSA level between 2.5-4.0 ng/ml. We believe further
studies involving larger series are necessary before more
definite conclusions can be drawn.
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